128 related articles for article (PubMed ID: 28278701)
1. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Iskierka-Jażdżewska E; Hus M; Giannopoulos K; Mądro E; Hołojda J; Piotrowska M; Zaucha JM; Piszczek W; Szeremet A; Wojciechowska M; Steckiewicz P; Knopińska-Posłuszny W; Osowiecki M; Drozd-Sokołowska J; Kumiega B; Kyrcz-Krzemień S; Hałka J; Dudziński M; Wieszczy P; Robak T; Warzocha K; Jamroziak K
Leuk Lymphoma; 2017 Oct; 58(10):2485-2488. PubMed ID: 28278701
[No Abstract] [Full Text] [Related]
2. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Winqvist M; Andersson PO; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Späth F; Hansson L; Österborg A;
Haematologica; 2019 May; 104(5):e208-e210. PubMed ID: 30514799
[No Abstract] [Full Text] [Related]
3. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Iskierka-Jażdżewska E; Puła B; Szeremet A; Hus M; Gołos A; Hołojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Zaucha JM; Warzocha K; Jamroziak K
Adv Clin Exp Med; 2019 Aug; 28(8):1051-1057. PubMed ID: 31199879
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Hillmen P; Diels J; Healy N; Iraqi W; Aschan J; Wildgust M
Haematologica; 2018 May; 103(5):e204-e206. PubMed ID: 29419428
[No Abstract] [Full Text] [Related]
6. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K
Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Solman IG; Blum LK; Hoh HY; Kipps TJ; Burger JA; Barrientos JC; O'Brien S; Mulligan SP; Kay NE; Hillmen P; Byrd JC; Lal ID; Dean JP; Mongan A
Leuk Res; 2020 Oct; 97():106432. PubMed ID: 32911375
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
10. The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
Molica S; Baumann TS; Lentini M; Levato L; Delgado J; Montserrat E
Leuk Res; 2020 Aug; 95():106401. PubMed ID: 32562875
[No Abstract] [Full Text] [Related]
11. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Elter T; James R; Busch R; Winkler D; Ritgen M; Böttcher S; Kahl C; Gassmann W; Stauch M; Hasan I; Staib P; Fischer K; Fink AM; Bahlo J; Bühler A; Döhner H; Wendtner CM; Stilgenbauer S; Engert A; Hallek M
Leukemia; 2012 Dec; 26(12):2549-52. PubMed ID: 22584787
[No Abstract] [Full Text] [Related]
12. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
Smolej L; Doubek M; Panovská A; Simkovič M; Brychtová Y; Belada D; Motyčková M; Mayer J
Leuk Res; 2012 Oct; 36(10):1278-82. PubMed ID: 22840362
[TBL] [Abstract][Full Text] [Related]
14. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE; Choi M; Cohen JB; Persky D; Danilov AV
Cancer; 2018 Aug; 124(15):3192-3200. PubMed ID: 29797667
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
Puła A; Stawiski K; Braun M; Iskierka-Jażdżewska E; Robak T
Leuk Lymphoma; 2018 May; 59(5):1084-1094. PubMed ID: 28891366
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
Jamroziak K; Szymczyk A; Hus M; Wojciechowska M; Knopinska-Posłuszny W; Hołojda J; Hałaburda K; Warzocha K; Iskierka-Jażdżewska E
Eur J Haematol; 2018 Apr; 100(4):389-391. PubMed ID: 29243346
[No Abstract] [Full Text] [Related]
18. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Hernández-Rivas JÁ; Qi K; Deshpande S; Parisi L; Wang M
Haematologica; 2019 May; 104(5):e211-e214. PubMed ID: 30442728
[No Abstract] [Full Text] [Related]
20. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Lenz G
J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
[No Abstract] [Full Text] [Related]
[Next] [New Search]